Circulating tumour cells as prognosis predictive markers of neoadjuvant chemotherapy-treated breast cancer patients

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12(6):335–43.
   PubMed Web of Science ®Google Scholar
• Gralow JR, Zujewski JA, Winer E. Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol. 2008;26(5):696–7.
   PubMed Web of Science ®Google Scholar
• Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351–7.
   PubMed Web of Science ®Google Scholar
• Untch M, Fasching P, Bauerfeind I. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: a preplanned interim analysis of efficacy at surgery. Program and Abstracts of the 44th American Society of Clinical Oncology Annual Meeting; 2008.
   Google Scholar
• Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8(6):369–77.
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010;16(9):2634–45.
   PubMed Web of Science ®Google Scholar
• Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet. 2014;15(4):406–14.
   PubMed Web of Science ®Google Scholar
• Krebs MG, Sloane R, Priest L, Lancashire L, Hou J-M, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29(12):1556–63.
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13(3):920–8.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.
   PubMed Web of Science ®Google Scholar
• Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14):4218–24.
   PubMed Web of Science ®Google Scholar
• Miller MC, Doyle GV, Terstappen L. Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421.
   PubMedGoogle Scholar
• Gires O, Stoecklein N. Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences. Cell Mol Life Sci. 2014;71(22):4393–402.
   PubMed Web of Science ®Google Scholar
• Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122–8.
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–4.
   PubMed Web of Science ®Google Scholar
• Alix-Panabières C, Mader S, Pantel K. Epithelial-mesenchymal plasticity in circulating tumor cells. J Mol Med. 2017;95(2):133–42.
   PubMed Web of Science ®Google Scholar
• Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, et al. Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol. 2011;2011:252361.
   PubMedGoogle Scholar
• Li Y, Ma G, Zhao P, Fu R, Gao L, Jiang X, et al. Improvement of sensitive and specific detection of circulating tumor cells using negative enrichment and immunostaining-FISH. Clin Chim Acta. 2018;485:95–102.
   PubMed Web of Science ®Google Scholar
• Li Y, Tian X, Gao L, Jiang X, Fu R, Zhang T, et al. Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer. Cancer Med. 2019;8(8):3782–92.
   PubMed Web of Science ®Google Scholar
• Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi L-A, Yap JT, et al. New Response Evaluation Criteria in Solid Tumors (revised RECIST guideline, version 1.1) in advanced non-small-cell lung cancer: comparison with the original RECIST (version 1.0) and its impact on assessment of tumor response to therapy. Am J Roentgenol. 2010;195(3):W221–W8.
   PubMed Web of Science ®Google Scholar
• Yao X, Hosenpud J, Chitambar CR, Charlson J, Cheng YC. A phase II study of concurrent docetaxel, epirubicin and cyclophosphamide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer. J Cancer. 2012;3:145–51.
   PubMed Web of Science ®Google Scholar
• Gabriel MT, Calleja LR, Chalopin A, Ory B, Heymann D. Circulating tumor cells: a review of non-EpCAM-based approaches for cell enrichment and isolation . Clin Chem. 2016;62(4):571–81.
   PubMed Web of Science ®Google Scholar
• Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacol Ther. 2016;157:120–4.
   PubMed Web of Science ®Google Scholar
• Haber DA, Velculescu V. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4(6):650–61.
   PubMed Web of Science ®Google Scholar
• Azim Jr HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, et al. Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial. Breast. 2013;22(6):1060–5.
   PubMed Web of Science ®Google Scholar
• Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, Huober J, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant “Geparquattro” trial. Clin Cancer Res. 2017;23(18):5384–93.
   PubMed Web of Science ®Google Scholar
• Pierga J-Y, Bidard F-C, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14(21):7004–10.
   PubMed Web of Science ®Google Scholar
• Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018;110(6):560–7.
   PubMedGoogle Scholar
• Parekh T, Dodwell D, Sharma N, Shaaban A. Radiological and pathological predictors of response to neoadjuvant chemotherapy in breast cancer: a brief literature review. Pathobiology. 2015;82(3–4):124–32.
   PubMed Web of Science ®Google Scholar
• Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124(2):403–12.
   PubMed Web of Science ®Google Scholar
• Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27(31):5153–9.
   PubMed Web of Science ®Google Scholar
• Ma S, Ling F, Gui A, Chen S, Sun Y, Li Z. Predictive value of circulating tumor cells for evaluating short- and long-term efficacy of chemotherapy for breast cancer. Med Sci Monit. 2017;23:4808–16.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 2010;17(3):199–204.
   PubMed Web of Science ®Google Scholar
• Chikaishi Y, Yoneda K, Ohnaga T, Tanaka F. EpCAM-independent capture of circulating tumor cells with a ‘universal CTC-chip’. Oncol Rep. 2017;37(1):77–82.
   PubMed Web of Science ®Google Scholar